Improving Mitral Repair for Functional Mitral Regurgitation
Key facts
- Who runs it
- Emory University
- Where
- Atlanta, United StatesSee the 3 sites
- Trial code
- Status
- Terminated
- People taking part
- 34 people enrolled
- Started
- 20 Mar 2018
- Ended
- 31 Dec 2023
- Type of study
- Interventional, 3 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Undersizing Mitral Annuloplasty
- Papillary Muscle Approximation
- Record updated
- 16 January 2025
- Why it stopped
- The study was terminated due to poor enrollment during COVID-19, which also hindered postoperative testing. With insufficient enrollment to meet trial goals, funds were redirected to animal studies on the same clinical issues.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Mitral regurgitation of moderate or greater severity, as defined by the guidelines of the American Society of Echocardiography (via a transthoracic echo)
- Cardiomyopathy of ischemic or non-ischemic origins, with or without the need for coronary revascularization
- Concomitant right-sided valve repair or replacement (i.e. patients requiring concomitant tricuspid procedures)
- Able to sign informed consent and release of medical information forms
Who cannot take part
- Prior mitral valve repair
- ST-segment elevation myocardial infarction within 14 days before inclusion in this study
- Congenital heart disease, except patent foramen ovale (PFO) or atrial septal defect (ASD)
- Recent history of psychiatric disease that is likely to impair compliance with the study protocol, in the judgement of the investigator
- Chronic renal insufficiency defined by creatinine ≥ 3.0 or chronic renal replacement therapy, who are contraindicated for cardiac surgery
- Any evidence of structural (chordal or leaflet) mitral lesions
- Contraindication for cardiopulmonary bypass
- Clinical signs of cardiogenic shock at the time of randomization
- Pregnancy at the time of randomization
Where in United States
- Emory St. Joseph's HospitalAtlanta, United States
- Emory University HospitalAtlanta, United States
- Emory University Hospital MidtownAtlanta, United States
About the trial
What the trial wants to find out
The investigators are interested in determining the best surgical technique to correct functional mitral regurgitation, as there is currently not one technique that is established to work better than the other.
Read full original descriptionShow less
The technique used in current clinical practice is undersizing mitral annuloplasty (UMA), in which a prosthetic ring is implanted onto the mitral valve to correct the leakage. Though widely adopted, durability of the repair is less, as 58% of the patients present with recurrent FMR within 2 years. There are no specific algorithms to predict who might have UMA failure, but research indicates that some geometric indices might be strong predictors. The investigators are interested in testing the hypothesis that, elevated lateral inter-papillary muscle separation (IPMS) is a predictor of post-UMA recurrence of FMR at 12 months. In the first part of this study, the study team will measure lateral IPMS before surgery and relate to post-surgery FMR severity at discharge/30 days, 6 months and 12 months.
A relatively newer technique is papillary muscle approximation (PMA), in which a suture draws together the two muscles that connect the mitral valve to the heart muscle prior to performing UMA. This reduces the lateral inter-papillary muscle separation (IPMS) and is expected to improve the durability of UMA. In the second part of this study, the investigators will perform PMA and UMA together and determine if FMR severity is reduced at discharge/30 days, 6 months and 12 months.
The 3 groups in the trial
- UMA (Group 1)Other group
Participants in the UMA group will receive an undersizing mitral annuloplasty (UMA).
Treatment: Undersizing Mitral Annuloplasty
- UMA + PMA (Group 2)Other group
Participants in the UMA + PMA group will receive an undersizing mitral annuloplasty (UMA) with papillary muscle approximation (PMA).
Treatment: Undersizing Mitral Annuloplasty and Papillary Muscle Approximation
- Retrospectively identified patientsNo study treatment, for comparison
Retrospectively identified patients, who already underwent the standard of care surgery for the lesion of interest at Emory, within 6 months (± 1 month) after the date of their surgery, and are suitable for recruitment to the study for their post-operative research.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 16 January 2025